PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-3.43%
Both companies show declining cash positions (-3.43% vs GNPX's -44.94%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-3.43%
Below half of GNPX's -44.94%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
967.92%
Above 1.5x GNPX's 29.64%. Michael Burry might investigate for potential short-term asset misclassification or risk.
-3.05%
Below half of GNPX's -37.99%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
0.98%
Below half GNPX's -20.18%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Less than half of GNPX's 5.72%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
0.98%
Below half of GNPX's 4.95%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-2.92%
Below half of GNPX's -31.77%. Michael Burry sees a potential red flag for stagnation or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-106.99%
Exceeding 1.5x GNPX's -9.94%. Michael Burry suspects ballooning short-term obligations vs. competitor.
16.37%
Less than half of GNPX's -20.16%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.35%
Less than half of GNPX's -100.00%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
2.58%
Less than half of GNPX's -20.16%. David Dodd sees far fewer liability expansions relative to competitor.
3.85%
Above 1.5x GNPX's 0.01%. Michael Burry suspects heavy new equity expansion or dilution.
-5.06%
0.5-0.75x GNPX's -7.12%. Martin Whitman is wary of weaker retention or lower profitability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.22%
Below half GNPX's -34.81%. Michael Burry sees potential underperformance in building shareholder capital.
-2.92%
Below half GNPX's -31.77%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-5.00%
Higher Total Debt Growth compared to GNPX's zero value, indicating worse performance.
3.39%
Less than half of GNPX's 44.94%. David Dodd sees better deleveraging or stronger cash buildup than competitor.